LEWOS BIOTECHNOLOGYNEUROSCIENCE · PRECLINICAL CROExplore · Discover · AdvanceNUCLEIC ACID DELIVERY
Compare siRNA, ASO, mRNA and delivery systems across routes, tissue distribution and expression or knockdown.
For nucleic-acid drugs, delivery often determines success. We compare candidates, carriers and routes under consistent conditions, quantify expression or knockdown in target tissues and identify the candidates and delivery strategies worth advancing.
For candidate-sequence screening, delivery-strategy comparison and target-tissue effect validation.
When sequences or carriers are designed and candidates or routes must be compared; when target-tissue expression or knockdown needs confirmation; or when delivery should connect to disease-model efficacy.
01Which candidate produces the clearest target-tissue effect?
02How do route changes alter distribution and target engagement?
03Do delivery, expression and knockdown results agree?
Choose an experiment combination around the research question. Steps, groups and timing are confirmed per project.
Confirm sequence, carrier, dose, route and target tissue.
Organize multi-route dosing and multi-tissue collection.
Measure expression or knockdown with qPCR and protein assays as needed.
Compare candidates and tissue differences to support advancement.
See how models map to endpoints, then open the topic page for model scope and representative evidence.
Nucleic-acid delivery does not depend on hTFR by default. The services connect only when a TfR1-targeted delivery mechanism is used.
DELIVERABLES
Deliverables are confirmed against the actual study scope and experiment combination.
Open the topics most directly related to this service for model scope and representative data.
Tell us your candidate type, study goal and development stage. We will help identify the experiment combination for Nucleic acid delivery & efficacy.
